Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. - Wikidata - awgldk - TriplyDB

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

http://www.wikidata.org/entity/Q37087894

about

Parenteral versus oral iron therapy for adults and children with chronic kidney disease Nanopharmaceuticals (part 2): products in the pipeline Body iron delocalization: the serious drawback in iron disorders in both developing and developed countries Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?Intravenous iron therapy: how far have we come?Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.Clinical Translation of Nanomedicine.Ferumoxytol for the treatment of iron deficiency.Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners.The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy Will nanotechnology influence targeted cancer therapy?Diagnosis and management of iron deficiency anemia in the 21st century.Iron dosing in kidney disease: inconsistency of evidence and clinical practice.Population pharmacokinetic meta-analysis to bridge ferumoxytol plasma pharmacokinetics across populations.Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol.Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging.Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure.Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia.Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients Safety and technique of ferumoxytol administration for MRI.Iron deficiency anemia in patients with inflammatory bowel disease.Materials characterization of Feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia Applications of nanoparticles in the detection and treatment of kidney diseases Use of agents stimulating erythropoiesis in digestive diseases Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.MRI with ferumoxytol: A single center experience of safety across the age spectrum Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography.Magnetic nanoparticles for cancer diagnosis and therapy.Ferric carboxymaltose for the treatment of iron-deficiency anemia. [corrected].

P2860

Q24203895-60776F19-C6E0-4FA6-ADDD-5FC195DF30ED Q26824153-19967C01-1540-4729-8921-0FC0740D0895 Q26824358-0C8AB6EF-9141-46DC-8D36-0BE5CDBC5B1A Q26829377-9A7B41EE-E087-42E5-A3F4-9C886BB4EC52 Q28088503-79E19925-4F41-4708-9015-ABB0C65648CC Q28276678-5DD08CA3-2B26-4E7B-918D-33C4D6B44FCC Q30234702-75ACCD45-764E-4C58-97C4-2C68F65EF03A Q30355939-42D800BD-0F16-4E6A-8665-46848530FA0F Q30454001-C67F6651-215E-4F28-A336-2C196D39E747 Q30838654-3B0612AF-5985-4F94-B07D-8CA2D66EE456 Q33700880-A1880824-21AF-40DA-B927-14FC1A45CADB Q34000965-80641E90-3A61-4664-8D78-F9A73514DE17 Q34085240-215D6339-D979-42FD-B5B3-D778A6252A6C Q34470847-60489FE0-9E35-4B09-8946-A0F8C22F04CD Q34477467-62173736-4B3D-4A8F-B91B-2486BAEC2BAD Q34706794-A7D3BDD5-F41A-4B7B-8E13-6F1FD62CCC7E Q35018420-6F794CC1-4B72-44C8-9200-3C2A4BA11F34 Q35022235-9CFDAAE1-2E70-49AE-9CD0-514DEDF94771 Q35203534-4622CDA8-DB5D-4AA6-BAAF-715CCFD98532 Q35574227-9BDAB303-FAA6-4B89-94CC-563C87CFC4B7 Q35812836-4053E31D-9A7A-4AF2-9AEA-C688D64B4044 Q35857178-D44931F0-7C84-4303-8C5F-73371B7EB00B Q36263980-5ABF1800-EA79-4048-87C2-F62FB129772F Q36346171-A531910A-0D41-4029-AAAE-4D691C18EF5B Q36371086-1B79F0F2-505C-459B-856B-64BE3FB91CE8 Q36664896-7AE005F2-74BC-4B0D-B59C-648C1E24B4BF Q36790975-ACF91ACF-9FCB-4737-BB5A-B61CC7295832 Q36862859-536744EF-F7D1-4E40-B545-1019967B7BF8 Q36918762-677699D6-7433-42F2-80DE-E49B4729AFC8 Q37225048-FB4BDADB-1E81-4413-BFD7-EC7ACB52389F Q37298541-48038F21-117C-4F53-A217-2EA9742611E2 Q37368733-F9B02118-1983-45E9-84C3-1061C990166A Q37587226-D0D4FBDC-09CE-4891-9F30-8FCD38C42C18 Q37622520-264F7B8C-3575-4711-8C8A-B84C6F539E92 Q37661506-01B7EBA3-5EE7-4733-8123-A2F0B6F6D070 Q37682229-9552EA78-6049-477C-929B-6A9C3186EE05 Q37838114-F34ABEB0-24B3-4BBF-AF35-D8DAE61B0563 Q37951906-F6BDA46E-2BC4-4022-A029-77334C896FDA Q37978479-7C0BB74F-10E7-41B6-B770-9DE4B40AF4AC Q37993131-D6FAA604-C7C6-4764-8DB3-E08A13E66E28

P2860

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

http://www.wikidata.org/entity/Q37087894

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

@en

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

@nl

type

label

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

@en

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

@nl

prefLabel

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

@en

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

@nl

P1433

Q37087894-106DC399-2969-4AA9-8B2D-96A123AA25FA

P1476

Q37087894-9B898F88-A8CE-45FC-A7DA-C2998958BDCB

P2093

Q37087894-09A6B558-50E3-4334-963C-AE3F0C290DC1

Q37087894-44413964-9104-43A9-9FB3-EE475364143F

Q37087894-62CD1B3A-6A2B-4440-A49F-240F2E2FD43C

Q37087894-BEC86E6B-BB4A-47C1-B612-0E8A6C25A605

Q37087894-BF5910F2-640B-44B7-A9A0-F6A776E11144

Q37087894-CDE06208-498A-49F6-8018-7CA910B6000F

P2860

Q37087894-050D8F56-8725-4DE7-B533-52FB6936E3DF

Q37087894-09C107E8-FB01-4738-8134-D7AD2C0747DD

Q37087894-1266F47B-77C8-47D7-BDDA-F50CEDCC98C7

Q37087894-12F74453-01CA-490C-9AF7-375406E2BB7C

Q37087894-1E1228C9-90A9-4871-827B-B46A978C4CAF

Q37087894-1F024152-CE80-4716-AC68-69997DB13213

Q37087894-26B3BE5F-884C-48F2-8D42-48EACA48C1EF

Q37087894-26C25357-D74B-4F13-B504-C69DC773E642

Q37087894-315FF72E-BEFA-44F6-95DD-531CF058AC7F

Q37087894-35665FF2-7DD8-4C3C-8FEF-29ACA1CEFF28

P304

Q37087894-3AB62176-9033-4500-B740-792EDEE16A4C

P31

Q37087894-F6CF1C17-19BC-47C5-92B0-DB67EF8D51EB

P356

Q37087894-6AF1F9B1-8883-4D96-AD66-F1F92BECDA76

P433

Q37087894-49F519F3-A0F0-40A9-910B-BBC1933240AD

P478

Q37087894-49A0C100-0597-4A38-86AE-7250668EC6E2

P577

Q37087894-1676E5CB-34A3-40BD-B30A-8122B0F4A0C5

P698

Q37087894-6624033B-17AF-468A-9FA4-892796195EAA

P921

Q37087894-69370A64-DA25-4928-BC7F-4C9748A5B309

P932

Q37087894-B1A8EE07-5576-4BE9-8A6F-97665FFCC60A

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

@en

P2093

Brian J G Pereira

http://www.w3.org/2001/XMLSchema#string

Brigitte Schiller

http://www.w3.org/2001/XMLSchema#string

Daniel Coyne

http://www.w3.org/2001/XMLSchema#string

Louis Brenner

http://www.w3.org/2001/XMLSchema#string

Madhumathi Rao

http://www.w3.org/2001/XMLSchema#string

Robert Provenzano

http://www.w3.org/2001/XMLSchema#string

P2860

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

A randomized controlled study of iron supplementation in patients treated with erythropoietin

Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients.

Low-molecular-weight protein-permeable cuprammonium rayon haemofilter.

Strategies for iron supplementation: oral versus intravenous.

Iron requirements in erythropoietin therapy.

Resolving the paradigm crisis in intravenous iron and erythropoietin management.

Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.

Ferumoxytol for treating iron deficiency anemia in CKD

Labile iron in parenteral iron formulations: a quantitative and comparative study.

P304

386-393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.02840608

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19176796

http://www.w3.org/2001/XMLSchema#string

P921

P932

2637590

http://www.w3.org/2001/XMLSchema#string